The minimal model was proposed over 25 years ago. Despite (or because of) its simplicity it continues to be used today – both as a clinical tool and an approach to understanding the composite effects of insulin secretion and insulin sensitivity on glucose tolerance and risk for type 2 diabetes mellitus. The original assumptions of the model have led to an understanding of the kinetics of insulin in vivo, as well as the relative importance of β-cell compensatory failure in the pathogenesis of diabetes. The disposition index (DI), a parameter emerging from the model, represents the ability of the pancreatic islets to compensate for insulin resistance. There is evidence that a locus on chromosome 11 codes for the DI, which has a significant heritability and can predict type 2 diabetes better than any known genetic locus. Even today, the model continues to be a subject of scientific discovery and discourse.

1.
Topor ZL, Pawlicki M, Remmers JE: A computational model of the human respiratory control system: responses to hypoxia and hypercapnia. Ann Biomed Eng 2004;32:1530–1545.
2.
Guyton AC: Circulatory Physiology: Cardiac Output and Its Regulation. Philadelphia, PA, Saunders, 1963.
3.
Bolie VW: Coefficients of normal blood glucose regulation. J Appl Physiol 1961;16:783–788.
4.
Srinivasan R, Kadish AH, Sridhar R: A mathematical model for the control mechanism of free fatty acid-glucose metabolism in normal humans. Comput Biomed Res 1970;3:146–165.
5.
Grodsky GM: A threshold distribution hypothesis for packet storage of insulin and its mathematical modeling. J Clin Invest 1972;51:2047–2059.
6.
Bergman RN: Pathogenesis and prediction of diabetes mellitus: lessons from integrative physiology. Mt Sinai J Med 2002;69:280–290.
7.
Galante P, Mosthaf L, Kellerer M, Berti L, Tippmer S, Bossenmaier B, Fujiwara T, Okuno A, Horikoshi H, Haring HU: Acute hyperglycemia provides an insulin-independent inducer for GLUT4 translocation in C2C12 myotubes and rat skeletal muscle. Diabetes 1995;44:646–651.
8.
Bergman RN, Ider YZ, Bowden CR, Cobelli C: Quantitative estimation of insulin sensitivity. Am J Physiol 1979;236:E667–E677.
9.
Zethelius B, Lithell H, Hales CN, Berne C: Insulin sensitivity, proinsulin and insulin as predictors of coronary heart disease. A population-based 10-year, follow-up study in 70-year old men using the euglycaemic insulin clamp. Diabetologia 2005;48:862–867.
10.
Pacini G, Bergman RN: MINMOD: a computer program to calculate insulin sensitivity and pancreatic responsivity from the frequently sampled intravenous glucose tolerance test. Comput Methods Programs Biomed 1986;23:113–122.
11.
Boston RC, Stefanovski D, Moate PJ, Sumner AE, Watanabe RM, Bergman RN: MINMOD Millennium: a computer program to calculate glucose effectiveness and insulin sensitivity from the frequently sampled intravenous glucose tolerance test. Diabetes Technol Ther 2003;5:1003–1015.
12.
Bergman RN, Phillips LS, Cobelli C: Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and Β-cell glucose sensitivity from the response to intravenous glucose. J Clin Invest 1981;68:1456–1467.
13.
Bergman RN: Toward physiological understanding of glucose tolerance: the minimal model approach. Lilly Award Lecture. Diabetes 1989;38:1512–1527.
14.
Letiexhe MR, Desaive C, Lefebvre PJ, Scheen AJ: Intact cross-talk between insulin secretion and insulin action after postgastroplasty recovery of ideal body weight in severely obese patients. Int J Obes Relat Metab Disord 2004;28:821–823.
15.
Buchanan TA, Metzger BE, Freinkel N, Bergman RN: Insulin sensitivity and β-cell responsiveness to glucose during late pregnancy in lean and moderately obese women with normal glucose tolerance or mild gestational diabetes. Am J Obstet Gynecol 1990;162:1008–1014.
16.
Stumvoll M, Tataranni PA, Bogardus C: The hyperbolic law – a 25-year perspective. Diabetologia 2005;48:207–209.
17.
Gladwell M: The Tipping Point: How Little Things Can Make a Big Difference. Boston, Little, Brown and Company, 2000.
18.
Azen SP, Peters RK, Berkowitz K, Kjos S, Xiang A, Buchanan TA: TRIPOD (TRoglitazone In the Prevention Of Diabetes): a randomized, placebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus. Control Clin Trials 1998;19:217–231.
19.
Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M; Finnish Diabetes Prevention Study Group: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343–1350.
20.
Lyssenko V, Almgren P, Anevski D, Perfekt R, Lahti K, Nissen M, Isomaa B, Forsen B, Homstrom N, Saloranta C, Taskinen MR, Groop L, Tuomi T; Botnia study group: Predictors of and longitudinal changes in insulin sensitivity and secretion preceding onset of type 2 diabetes. Diabetes 2005;54:166–174.
21.
Rich SS, Bowden DW, Haffner SM, Norris JM, Saad MF, Mitchell BD, Rotter JI, Langefeld CD, Wagenknecht LE, Bergman RN: Insulin Resistance Atherosclerosis Family Study: Identification of quantitative trait loci for glucose homeostasis: the Insulin Resistance Atherosclerosis Study (IRAS) Family Study. Diabetes 2004;53:1866–1875.
22.
Valle T, Tuomilehto J, Bergman RN, Ghosh S, Hauser ER, Eriksson J, Nylund SJ, Kohtamaki K, Toivanen L, Vidgren G, Tuomilehto-Wolf E, Ehnholm C, Blaschak J, Langefeld CD, Watanabe RM, Magnuson V, Ally DS, Hagopian WA, Ross E, Buchanan TA, Collins F, Boehnke M: Mapping genes for NIDDM: design of the Finland–United States Investigation of NIDDM Genetics (FUSION) Study. Diabetes Care 1998;21:949–958.
23.
Bergman RN, Ader M, Huecking K, Van Citters GW: Accurate assessment of beta-cell function: the hyperbolic correction. Diabetes 2002;51(suppl 1):S212–S220.
24.
Mittleman SD, Van Citters GW, Kim SP, Davis DA, Dea MK, Bergman RN: The longitudinal compensation for fat induced insulin resistance includes reduced insulin clearance and enhanced beta-cell response. Diabetes 2000;49:2116–2125.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.